Preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated intensive care unit patients (NEBULAE): study protocol for a randomized controlled trial

van der Hoeven, SM; Binnekade, JM; de Borgie, CAJM; Bosch, FH; Endeman, H; Horn, J; Juffermans, NP; van der Meer, NJM; Merkus, MP; Moeniralam, HS; van Silfhout, B; Slabbekoorn, M; Stilma, W; Wijnhoven, JW; Schultz, MJ; Paulus, F

Journal article

Preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated intensive care unit patients (NEBULAE): study protocol for a randomized controlled trial

Abstract:: Preventive nebulization of mucolytic agents and bronchodilating drugs is a strategy aimed at the prevention of sputum plugging, and therefore atelectasis and pneumonia, in intubated and ventilated intensive care unit (ICU) patients. The present trial aims to compare a strategy using the preventive nebulization of acetylcysteine and salbutamol with nebulization on indication in intubated and ventilated ICU patients. The preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated intensive care unit patients (NEBULAE) trial is a national multicenter open-label, two-armed, randomized controlled non-inferiority trial in the Netherlands. Nine hundred and fifty intubated and ventilated ICU patients with an anticipated duration of invasive ventilation of more than 24 hours will be randomly assigned to receive either a strategy consisting of preventive nebulization of acetylcysteine and salbutamol or a strategy consisting of nebulization of acetylcysteine and/or salbutamol on indication. The primary endpoint is the number of ventilator-free days and surviving on day 28. Secondary endpoints include ICU and hospital length of stay, ICU and hospital mortality, the occurrence of predefined pulmonary complications (acute respiratory distress syndrome, pneumonia, large atelectasis and pneumothorax), and the occurrence of predefined side effects of the intervention. Related healthcare costs will be estimated in a cost-benefit and budget-impact analysis. The NEBULAE trial is the first randomized controlled trial powered to investigate whether preventive nebulization of acetylcysteine and salbutamol shortens the duration of ventilation in critically ill patients. NCT02159196, registered on 6 June 201

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

van der Hoeven, S. M., Binnekade, J. M., de Borgie, C. A. J. M., Bosch, F. H., Endeman, H., Horn, J., Juffermans, N. P., van der Meer, N. J. M., Merkus, M. P., Moeniralam, H. S., van Silfhout, B., Slabbekoorn, M., Stilma, W., Wijnhoven, J. W., Schultz, M. J., & Paulus, F. (2015). Preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated intensive care unit patients (NEBULAE): study protocol for a randomized controlled trial. Trials, 16(1), 389–389.

MLA Style

van der Hoeven, SM, et al. “Preventive Nebulization of Mucolytic Agents and Bronchodilating Drugs in Invasively Ventilated Intensive Care Unit Patients (NEBULAE): Study Protocol for a Randomized Controlled Trial.” Trials, vol. 16, no. 1, 2015, pp. 389–89.

Chicago Style

Hoeven, SM van der, JM Binnekade, CAJM de Borgie, et al. 2015. “Preventive Nebulization of Mucolytic Agents and Bronchodilating Drugs in Invasively Ventilated Intensive Care Unit Patients (NEBULAE): Study Protocol for a Randomized Controlled Trial.” Trials 16 (1): 389–89.
Print